As I've posted a few times earlier, I just don't see any DEA re-classification happening now given the federal restraints on legal research and the paucity of positive research data, among other reasons. The clause Sleek recently posted opening door for legally based cannabis research, makes timely sense to me, supports the future possibility of DEA re-consideration and supports my earlier posted conjecture.
For discussion sake, let's say thee is no DEA re-classification upon us, what then is your conjecture regarding BOB, the financing picture of which you speak to and the resulting impact on investor sentiment?